Clinical trials: Postmenopausal Disorder
Breast Cancer
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a…
- Trial name
- NCT01300351
- Testing
- Fulvestrant
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- AstraZeneca
Osteopenia, Osteoporosis
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
The purpose of this study is to evaluate the changes in bone structure as determined by magnetic resonance imaging measurements among early postmenopausal women after 24 months of treatment with alendronate, 70 mg once a week as…
- Trial name
- NCT00504166
- Testing
- alendronate sodium
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Protocol for Women at Increased Risk of Developing Breast Cancer
A pilot study to assess the effects of six months of letrozole on breast tissue risk markers in postmenopausal women on hormone replacement therapy at high risk of developing breast cancer.
- Trial name
- NCT00291135
- Testing
- letrozole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Carol Fabian, MD
Early Breast Cancer
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
Evaluating the safety, tolerability and efficacy of Aromasin® when used in routine clinical practice, evaluating adherence to prescribed Aromasin® treatment and to understand reasons for early discontinuation.
- Trial name
- NCT01155063
- Testing
- Aromasin (exemestane)
- Volunteers
- 89 people
- Sponsor
- Pfizer
Atrophy, Vaginal Diseases
A Clinical Study to Evaluate the Safety of Ospemifene
The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.
- Trial name
- NCT00566982
- Testing
- Ospemifene 60 mg
- Volunteers
- 426 people
- Sponsor
- Shionogi
Vaginosis, Vaginosis, Bacterial
Postmenopausal Pessary Users: Estrogen Versus Trimosan
The purpose of the study is to compare vaginally applied estrogen with the vaginal gel trimosan for their effects on vaginal pH and vaginal symptoms in postmenopausal pessary users.
- Conditions
- Vaginosis, Vaginosis, Bacterial, Vaginal Discharge
- Trial name
- NCT03943823
- Testing
- Estrogen vaginal cream, Trimo-San vaginal gel
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center, Houston
Osteoporotic Fractures, Osteoporosis, Postmenopausal
A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women
This proposed study was designed to investigate the prevalence of a 5-year incident osteoporotic fracture and evaluate the association of a 5-year change of 25-hydroxyvitamin D (25[OH]D)/bone turnover makers/bone mineral density…
- Trial name
- PK-VF (NCT02247011)
- Testing
- Questionaire survey, Bone mineral density examination, Vertebral fracture assessment
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Sexual Dysfunction, Physiological
Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
Vulvovaginal atrophy (VVA) is a condition that impacts up to 60% of the growing postmenopausal female population, and the most common symptom is dyspareunia.
- Trial name
- NCT03018106
- Testing
- Ospemifene, Vaginal conjugated estrogens
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
This randomized phase II trial is studying how well giving gefitinib together with anastrozole works compared to giving gefitinib together with fulvestrant in treating postmenopausal women with recurrent or metastatic breast…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00057941
- Testing
- anastrozole, gefitinib, fulvestrant
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Postmenopausal Osteoporosis
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.
- Trial name
- NCT01750086
- Testing
- Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Osteopenia
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
The main purpose of this study is to assess the safety, tolerability and potential immune response to romosozumab following single subcutaneous (SC; injection under the skin) dose administration in healthy postmenopausal Japanese…
- Trial name
- NCT01101061
- Testing
- Romosozumab
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
This study is designed to provide information about the bone anabolic properties and absorption profile of Unigene's PTH Analog when administered as oral tablets over a period of 24 weeks to postmenopausal women with osteoporosis.
- Trial name
- NCT01321723
- Testing
- PTH analog, Forsteo (Teriparatide)
- Where
- 4 sites in Denmark, Estonia
- Volunteers
- 97 people
- Sponsor
- Unigene Laboratories Inc.
Vulvovaginal Atrophy, Menopause
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.
- Conditions
- Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
- Trial name
- REJOICE (NCT02253173)
- Testing
- Estradiol
- Where
- 105 sites in United States, Canada
- Volunteers
- 764 people
- Sponsor
- TherapeuticsMD
Urinary Tract Infections
Nutraceutical Efficacy for rUTI
This is a study designed to evaluate the efficacy of a nutraceutical as a non-antibiotic treatment to prevent recurrent urinary tract infections in women that have completed menopause and are on vaginal estrogen therapy.
- Trial name
- NCT03395288
- Testing
- D-Mannose
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Sexual Dysfunctions, Psychological
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
- Trial name
- NCT01188603
- Testing
- flibanserin 100 mg dose every evening
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Postmenopausal Women, Locally Advanced Metastatic Breast Cancer
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
This was a multi-center, Israeli phase II open label study evaluating treatment with RAD001 (10 mg daily) combined with letrozole (2.5 mg daily) in postmenopausal women after recurrence or progression on Tamoxifen, Anastrozole or…
- Conditions
- Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT01231659
- Testing
- Everolimus, Letrozole
- Where
- 7 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women
The study plans to find out whether Celebrex may be potentially useful to decrease inflammation in fat tissues and thereby lower the production of substances such as estrogens that may increase the risk of developing breast…
- Trial name
- NCT01901679
- Testing
- Celebrex
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Osteoporosis, Osteopenia
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects…
- Trial name
- NCT00330460
- Testing
- Alendronate, Denosumab
- Volunteers
- 1,189 people
- Sponsor
- Amgen
Insulin Resistance
Timing Estrogen After MenoPaUSe
The aim of the current study is to test whether the effect of estrogen on insulin metabolism depends on the timing of treatment relative to when a woman went through menopause.
- Trial name
- TEMPUS (NCT01605071)
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health
The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus
- Trial name
- NCT00679939
- Testing
- Rosiglitazone, Metformin
- Where
- 42 sites in United States, Argentina and 6 more
- Volunteers
- 226 people
- Sponsor
- GlaxoSmithKline